United States ophthalmic goods industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Top Ophthalmic Goods Stocks in USA

Name: Top Ophthalmic Goods Stocks in USA comparison snapshot
Creator: Fliar BI Prism

Five U.S.-listed ophthalmic goods names, read through one evidence stack: market path, official filing history, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderWarby Parker · 47

Strongest available pathThe Cooper Companies · -37.0%

Widest latest marginThe Cooper Companies · 9.2%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1WRBY · NYSE

Warby Parker

A U.S.-listed issuer classified by the SEC in Ophthalmic Goods

Founded 2010New York City$3.09B market cap

View full Companies Radar profile

47Cautious

Snapshot price$25.00as of page date

Monthly-close return-52.4%five-year window

FY2025 revenue$0.87BWarby Parker Inc.

Net margin0.2%FY2025

P/E snapshot416.7xone ratio, not a verdict

Prism attention79.5%share across these five

Filing track recordRevenue, USD billions

+61.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.7%

52-week position63% through range

$14.96$31.00

News mentions10.4K

Community mentions1.1Kpartial coverage

U.S.-scope patents124

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal59/100
Management stability90/100
Market position3/100
Capital-event signal68/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2EYE · Nasdaq

National Vision

A U.S.-listed issuer classified by the SEC in Ophthalmic Goods

Founded 1990Lawrenceville, Georgia$1.37B market cap

View full Companies Radar profile

37Cautious

Snapshot price$17.38as of page date

Monthly-close return-70.2%five-year window

FY2025 revenue$1.99BNational Vision Holdings, Inc.

Net margin1.5%FY2025

P/E snapshot28.0xone ratio, not a verdict

Prism attention5.5%share across these five

Filing track recordRevenue, USD billions

-4.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -1.1%

52-week position17% through range

$14.75$30.02

News mentions716

Community mentions35partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal55/100
Management stability90/100
Market position7/100
Capital-event signal15/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3STAA · Nasdaq

STAAR Surgical

A U.S.-listed issuer classified by the SEC in Ophthalmic Goods

Founded 1982Wilmington$1.11B market cap

View full Companies Radar profile

35Cautious

Snapshot price$22.11as of page date

Monthly-close return-85.5%five-year window

FY2025 revenue$0.24BSTAAR SURGICAL CO

Net margin-33.6%FY2025

P/E snapshot276.4xone ratio, not a verdict

Prism attention11.3%share across these five

Filing track recordRevenue, USD billions

+3.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021, FY2022, FY2023, FY2024, FY2025 · CAGR 1.0%

52-week position32% through range

$15.59$35.87

News mentions1.5K

Community mentions0partial coverage

U.S.-scope patents135

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal28/100
Management stability55/100
Market position20/100
Capital-event signal60/100
Innovation pulse8/100

Management signal

Leadership churn is flagged elevated; 20 key-person events were recorded in the latest 360-day window.

Market activity

Available history contains 30 M&A involvements, 1 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4COO · Nasdaq

The Cooper Companies

A U.S.-listed issuer classified by the SEC in Ophthalmic Goods

Founded 1958Pleasanton$13.88B market cap

View full Companies Radar profile

35Cautious

Snapshot price$71.17as of page date

Monthly-close return-37.0%five-year window

FY2025 revenue$4.09BCOOPER COMPANIES, INC.

Net margin9.2%FY2025

P/E snapshot60.3xone ratio, not a verdict

Prism attention1.0%share across these five

Filing track recordRevenue, USD billions

+40.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 8.8%

52-week position40% through range

$58.89$89.83

News mentions135

Community mentions11partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal59/100
Management stability90/100
Market position0/100
Capital-event signal5/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5RXST · Nasdaq

RxSight

A U.S.-listed issuer classified by the SEC in Ophthalmic Goods

Founded 1997Aliso Viejo$293.2M market cap

View full Companies Radar profile

29Avoid

Snapshot price$7.05as of page date

Monthly-close return-57.0%five-year window

FY2025 revenue$0.13BRxSight, Inc.

Net margin-29.0%FY2025

P/E snapshot-10.1xone ratio, not a verdict

Prism attention2.7%share across these five

Filing track recordRevenue, USD billions

+495.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 56.2%

52-week position29% through range

$4.48$13.22

News mentions358

Community mentions13partial coverage

U.S.-scope patents145

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal26/100
Management stability90/100
Market position0/100
Capital-event signal25/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

The Cooper Companies

-37.0%

Warby Parker

-52.4%

RxSight

-57.0%

National Vision

-70.2%

STAAR Surgical

-85.5%

Latest revenue

USD billions, official filing scope shown on each company card.

The Cooper Companies

$4.09B

National Vision

$1.99B

Warby Parker

$0.87B

STAAR Surgical

$0.24B

RxSight

$0.13B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

The Cooper Companies

9.2%

National Vision

1.5%

Warby Parker

0.2%

RxSight

-29.0%

STAAR Surgical

-33.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Warby Parker

79.5%

STAAR Surgical

11.3%

National Vision

5.5%

RxSight

2.7%

The Cooper Companies

1.0%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized ophthalmic goods news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Warby Parker leads the conversation

It holds 79.5% of measured ophthalmic goods news attention and also carries the basket's largest revenue base at $0.87B.

Price path

The Cooper Companies leads the available price paths

Its monthly-close return is -37.0% for the five-year window. At the other end, STAAR Surgical is -85.5% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

The Cooper Companies has the widest latest margin

Its FY2025 net margin is 9.2%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

RxSight shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -10.1x while its five-year window price return is -57.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · WRBY

Warby Parker

10,376available Prism news records

Prism top themes

Price action & investor response

115

Earnings & financial performance

108

Leadership & governance

Macro demand & rates

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+4.7%1,383 latest 12m vs 1,321 prior 12m

Machine-classified coverage tone

91.8% positive+9.1 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

smart glasses 331google glass 316enterprise glasses 315assistive glasses 278vr glasses 273display eyewear 234wearable display 219ar glasses 205

Keyword tag occurrences in available Prism news records.

Coverage: 2010-06-30–2026-08-02 · trend and themes shown through 2026-08

Areas of research · STAA

STAAR Surgical

1,475available Prism news records

Prism top themes

Capital allocation & transactions

Earnings & financial performance

Leadership & governance

Price action & investor response

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+114.5%399 latest 12m vs 186 prior 12m

Machine-classified coverage tone

70.1% positive-9.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

merger update 37acquisition news 21shareholder vote 18earnings report 14stock price 14ophthalmoscope 11corporate consolidation 11stock surge 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-04 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

WRBY

Warby Parker

1,091 mentions

Products, pricing and logistics

594

Stock and valuation

Workplace and hiring

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 1,091 records remained after filtering.

EYE

National Vision

35 mentions

Stock and valuation

Workplace and hiring

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 35 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

WRBY

Warby Parker

through 2026-02-27

Earnings releases 46Company announcements 17Leadership changes 7

2026-02-27
Earnings releases
Annual net revenue increased 13% to $871.9 million and active customers grew 7%, while average revenue per customer rose 5.7% year over year to $324, reflecting gains from premium lenses, contacts and multi-pair purchases.
2026-02-11
Leadership changes
Warby Parker Inc. announced in its Q2/25 earnings press release that its CFO was stepping down
2025-08-23
Company announcements
It is preparing to open its first New Jersey location at Westfield Garden State Plaza in Paramus.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EYE

National Vision

through 2026-03-06

Earnings releases 18Leadership changes 12Lawsuits 9Company announcements 4Business contracts 1

2026-03-06
Earnings releases
For fiscal 2025, National Vision reported net revenue growth of 9% to $1.99 billion and adjusted comparable store sales growth of 6%.
2025-01-17
Leadership changes
Megan Molony will now lead Manufacturing and Distribution, Mark Banner has been appointed as President of America’s Best, and Dr. Priti Patel has taken on the role of General Manager of Eyeglass World, Fred Meyer, and Military.
2024-11-06
Company announcements
Additionally, the Company will convert four Eyeglass World stores to America’s Best stores during fiscal 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

STAA

STAAR Surgical

through 2026-04-09

Earnings releases 42Leadership changes 33M&A 30Board updates 2Lawsuits 2

2026-04-09
Earnings releases
Net sales for the first quarter of 2026 are expected to be in excess of $90 million, compared with net sales of $42.6 million for the first quarter of 2025, according to the announcement from the company.
2026-03-03
Company announcements
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 after the market close.
2026-02-16
M&A
Credit Industriel ET Commercial bought 121,258 shares of the medical instruments supplier’s stock, valued at approximately $3,258,000.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

COO

The Cooper Companies

through 2025-12-05

Earnings releases 7Company announcements 1Leadership changes 1

2025-12-05
Earnings releases
Revenues totaled $1.065 billion, up 5% year over year on a reported basis and up 3% organically.
2025-02-14
Leadership changes
The Cooper Companies (Pleasanton California/Lake Forest, California), a manufacturer of specialty healthcare products through its CooperVision and CooperSurgical units, yesterday reported that its board has elected Robert Weiss as its CEO, succeeding A. Thomas Bender, effective Nov. 1, the beginning of FY09 for the company.
2023-07-24
Company announcements
In February 2022, The Cooper Companies Inc., a global medical device company, announced that it has signed a binding letter of intent to acquire Cook Medical's Reproductive Health business, a manufacturer of minimally invasive medical devices focused on the fertility, obstetrics and gynecology markets. Cooper will pay approximately US$ 875 million comprised of US$ 675 million at closing and US$ 200 million paid in four US$ 50 million annual installments.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RXST

RxSight

through 2026-02-27

Earnings releases 31Listing / IPO 3Leadership changes 1

2026-02-27
Earnings releases
Full-year 2025 global sales decreased 4 percent to $134.5 million compared with the previous year, the company reported...
2026-01-05
Leadership changes
To lead this expansion, the company hired Adam Dashe as executive vice president of international in the third quarter.
2024-05-09
Listing / IPO
RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Ophthalmic Goods Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary ophthalmic goods news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

ophthalmic devices market

15 sources70.2% extraction confidence

2021 extracted base$35.70B–$68.20B

2027 extracted forecast$46.30B–$66.71B

Implied source CAGR5.1%

aging populationtechnological advancementsrising geriatric population

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Europe, United States, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Ophthalmic Goods news pulse

50,845available Prism news records

Latest 12m volume-9.5%20658 vs 22834 records

Positive classified tone83.9%+9.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching good, ophthalmic, device. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

3d printers and additive manufacturing devices

2,350

medical device integration with biotech

2,276

semiconductor devices and components

2,100

wearable technology and smartwatches

1,732

trade policies and agreements

1,672

counterfeit goods & ip enforcement

1,616

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

goods trade gap 4,059bilateral trade imbalance 3,915trade barrier reduction 3,296trade facilitation commitments 2,335wearable device 1,727smartwatch 1,702bilateral trade terms 1,676tariff negotiations 1,661

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

aging population

15 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

3d printers and additive manufacturing devices

2,350 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

9,408 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

high cost of some devices

1,385 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

-9.5% news volume

The latest 12 months contain 20,658 matched records versus 22,834 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

83.9% positive · +9.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five currently eligible U.S.-listed issuers classified under SEC SIC 3851 (Ophthalmic Goods). The builder rechecks price, filing and Prism evidence before assembling the basket. This is a focused research comparison, not a complete sector index.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Ophthalmic Goods Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Warby Parker leads the readiness ranking

Its Prism readiness score is 47/100, the highest in this five-company comparison.

Open Warby Parker in Companies Radar

Scale and margin leadership sit with The Cooper Companies and The Cooper Companies

The Cooper Companies has the largest displayed latest revenue at $4.09B; The Cooper Companies has the widest displayed latest margin at 9.2%.

Open The Cooper Companies in Companies Radar

Comparisons

Strongest versus weakest available price path

The Cooper Companies is -37.0% for its five-year window; STAAR Surgical is -85.5% for its five-year window.

Open The Cooper Companies in Companies Radar Open STAAR Surgical in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $4.09B for The Cooper Companies to $0.13B for RxSight. Entity and filing-period labels remain visible on the company cards.

Open The Cooper Companies in Companies Radar Open RxSight in Companies Radar

Anomalies

STAAR Surgical has the widest attention-readiness rank gap

It ranks #2 by measured news attention (11.3%) and #3 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open STAAR Surgical in Companies Radar

RxSight shows a price-operating divergence to inspect

Its displayed filing-revenue change is +495.2% while its available monthly-close return is -57.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open RxSight in Companies Radar

Explanations

Attention measures coverage volume, not quality

Warby Parker's 79.5% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Warby Parker in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Warby Parker's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 47/100 score.

Open Warby Parker in Companies Radar

Stress-test the largest divergence before forming a view

Compare RxSight's profile with The Cooper Companies's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open RxSight in Companies Radar Open The Cooper Companies in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.